Non-GAAP net income may exclude unusual or non-recurring items that are evaluated on an individual basis. Our evaluation of whether to exclude an item for purposes of determining our non-GAAP financial measures considers both the quantitative and qualitative aspects of the item, including, among other things (i) its size and nature, (ii) whether or not it relates to our ongoing business operations, and (iii) whether or not we expect it to occur as part of our normal business on a regular basis. For purposes of determining non-GAAP net income, the asset impairment is excluded.
VIROPHARMA INCORPORATEDSelected Financial InformationSelected Consolidated Balance Sheet DataDecember 31,December 31,(in thousands)
20112010AssetsCurrent assets:Cash and cash equivalents
60,31654,388Total current assets
635,931633,141Intangible assets, net
1,336,7971,287,574Liabilities and Stockholders’ EquityTotal current liabilities
98,65172,122Deferred tax liabilities
445,673396,439Total stockholders’ equity
891,124891,135Total liabilities and stockholders’ equity
1,336,7971,287,574 Years Ended December 31,December 31,Statement of Cash Flows:20112010(in thousands)Net cash provided by operating activities
93,517Net cash used in investing activities
(101,934)Net cash (used in) provided by financing activities
|SOURCE ViroPharma Incorporated|
Copyright©2010 PR Newswire.
All rights reserved